Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Apr 18, 2017
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.    Manag...
Feb 28, 2017
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10...
Feb 21, 2017
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016. For the fourth quarter of 2016, the Company reported total revenues of $34.2 million, including $15.8 million in product revenues from Sandoz's sales of ...
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 8:00 a.m. ET on Tuesday, February 21, 2017.    To access the ca...
Feb 17, 2017
Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and...
Feb 17, 2017
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with...
Feb 7, 2017
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2016 before the U.S. financial markets open on Tuesday, February 21, 2...
Feb 1, 2017
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, February ...
Jan 31, 2017
CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the United States District Court for the District of Delaware has found each of Teva Pharmaceutical's U.S. Patent Nos. 8,232,250; 8,399,413; 8,969,302; and 9,155,776  invalid as obvious over the prior art. "We are very pleased...
Jan 6, 2017
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a $51M one-time return payment -- CAMBRIDGE, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology ...
1
...
NextLast
= add release to Briefcase